CompletedNCT05790252
Buprenorphine patch induction during pregnancy: BRIDGE study
About this title
Read the official source — NCT05790252Medication studyAges 18–110United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 110 years.
- Listed locations
- St LouisSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: November 27, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 7
- Sponsor
- Washington University School of Medicine
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 110 Years
- Official registry ID
- NCT05790252
- Official title
Show the full official title
Using the Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy: A Randomized Controlled Trial (The Patch BRIDGE Trial)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
St Louis
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Washington University School of Medicine, a university.
Did this study involve medication?
Yes. The study involved medication, including Buprenorphine Transdermal Matrix Patch.
Who was this study for?
Listed age limits: 18 years to 110 years.
